---
document_datetime: 2025-11-23 08:03:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/elocta.html
document_name: elocta.html
version: success
processing_time: 0.1252493
conversion_datetime: 2025-12-24 02:33:04.701986
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Elocta

[RSS](/en/individual-human-medicine.xml/65892)

##### Authorised

This medicine is authorised for use in the European Union

efmoroctocog alfa

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Elocta](#news-on)
- [More information on Elocta](#more-information-on-elocta-556)
- [More information on Elocta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Elocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). It contains the active substance efmoroctocog alfa.

Expand section

Collapse section

## How is Elocta used?

Elocta is available as a powder and solvent used to make a solution for injection. The injection is given into a vein over several minutes. The dose and frequency of the injections depend on whether Elocta is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.

Elocta can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia. For more information about using Elocta, see the package leaflet or contact your doctor or pharmacist.

## How does Elocta work?

Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Elocta, efmoroctocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.

Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Elocta, efmoroctocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.

## What benefits of Elocta have been shown in studies?

Two main studies of Elocta showed that the medicine is effective at both preventing and treating bleeding episodes.

In a study of 165 adult patients with haemophilia A, patients who were given Elocta as a tailored preventive treatment had around 3 bleeding episodes a year, which compares with 37 episodes a year in patients not given preventive treatment. In addition, when bleeding did occur, Elocta treatment was rated as 'excellent' or 'good' in more than 78% of cases, with 87% of bleeding episodes resolving with only one injection.

In a study in 69 children, Elocta was similarly effective: 2 bleeding episodes occurred per year on average and 81% of bleeding episodes resolved with only one injection.

## What are the risks associated with Elocta?

Hypersensitivity (allergic) reactions are seen rarely with Elocta and these include: swelling of the face, rash, hives, tightness of the chest and difficulty breathing, burning and stinging at the injection site, chills, flushing, itching over the whole body, headache, low blood pressure, lethargy, nausea, restlessness, and a fast heartbeat. In some cases these reactions can become severe.

There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.

For the full list of side effects and restrictions of Elocta, see the package leaflet.

## Why is Elocta authorised in the EU?

Studies show that Elocta is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is in line with what is expected for medicines of its kind. The European Medicines Agency therefore decided that Elocta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Elocta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elocta have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Elocta are continuously monitored. Side effects reported with Elocta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Elocta

Elocta received a marketing authorisation valid throughout the EU on 19 November 2015.

Elocta : EPAR - Medicine overview

Reference Number: EMA/660642/2015

English (EN) (73.56 KB - PDF)

**First published:** 10/12/2015

**Last updated:** 12/12/2018

[View](/en/documents/overview/elocta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-596)

български (BG) (99.19 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/bg/documents/overview/elocta-epar-medicine-overview_bg.pdf)

español (ES) (72.96 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/es/documents/overview/elocta-epar-medicine-overview_es.pdf)

čeština (CS) (95.03 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/cs/documents/overview/elocta-epar-medicine-overview_cs.pdf)

dansk (DA) (72.94 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/da/documents/overview/elocta-epar-medicine-overview_da.pdf)

Deutsch (DE) (73.87 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/de/documents/overview/elocta-epar-medicine-overview_de.pdf)

eesti keel (ET) (72.3 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/et/documents/overview/elocta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (104.97 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/el/documents/overview/elocta-epar-medicine-overview_el.pdf)

français (FR) (74.08 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/fr/documents/overview/elocta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (90.35 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/hr/documents/overview/elocta-epar-medicine-overview_hr.pdf)

italiano (IT) (72.76 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/it/documents/overview/elocta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (94.56 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/lv/documents/overview/elocta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (95.53 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/lt/documents/overview/elocta-epar-medicine-overview_lt.pdf)

magyar (HU) (92.77 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/hu/documents/overview/elocta-epar-medicine-overview_hu.pdf)

Malti (MT) (96.25 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/mt/documents/overview/elocta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.18 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/nl/documents/overview/elocta-epar-medicine-overview_nl.pdf)

polski (PL) (96.12 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/pl/documents/overview/elocta-epar-medicine-overview_pl.pdf)

português (PT) (73.47 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/pt/documents/overview/elocta-epar-medicine-overview_pt.pdf)

română (RO) (95.01 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/ro/documents/overview/elocta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.8 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/sk/documents/overview/elocta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (90.56 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/sl/documents/overview/elocta-epar-medicine-overview_sl.pdf)

Suomi (FI) (72.38 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/fi/documents/overview/elocta-epar-medicine-overview_fi.pdf)

svenska (SV) (73.29 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

12/12/2018

[View](/sv/documents/overview/elocta-epar-medicine-overview_sv.pdf)

Elocta : EPAR - Risk-management-plan summary

English (EN) (46.92 KB - PDF)

**First published:** 03/09/2020

[View](/en/documents/rmp-summary/elocta-epar-risk-management-plan-summary_en.pdf)

## Product information

Elocta : EPAR - Product Information

English (EN) (802.34 KB - PDF)

**First published:** 10/12/2015

**Last updated:** 25/04/2025

[View](/en/documents/product-information/elocta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-971)

български (BG) (628.13 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/bg/documents/product-information/elocta-epar-product-information_bg.pdf)

español (ES) (496.39 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/es/documents/product-information/elocta-epar-product-information_es.pdf)

čeština (CS) (727.12 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/cs/documents/product-information/elocta-epar-product-information_cs.pdf)

dansk (DA) (545.9 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/da/documents/product-information/elocta-epar-product-information_da.pdf)

Deutsch (DE) (728.73 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/de/documents/product-information/elocta-epar-product-information_de.pdf)

eesti keel (ET) (538.4 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/et/documents/product-information/elocta-epar-product-information_et.pdf)

ελληνικά (EL) (645.12 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/el/documents/product-information/elocta-epar-product-information_el.pdf)

français (FR) (583.65 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/fr/documents/product-information/elocta-epar-product-information_fr.pdf)

hrvatski (HR) (1017.71 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/hr/documents/product-information/elocta-epar-product-information_hr.pdf)

íslenska (IS) (567.42 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/is/documents/product-information/elocta-epar-product-information_is.pdf)

italiano (IT) (614.05 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/it/documents/product-information/elocta-epar-product-information_it.pdf)

latviešu valoda (LV) (616.59 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/lv/documents/product-information/elocta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (619.83 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/lt/documents/product-information/elocta-epar-product-information_lt.pdf)

magyar (HU) (632.54 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/hu/documents/product-information/elocta-epar-product-information_hu.pdf)

Malti (MT) (657.65 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/mt/documents/product-information/elocta-epar-product-information_mt.pdf)

Nederlands (NL) (501.75 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/nl/documents/product-information/elocta-epar-product-information_nl.pdf)

norsk (NO) (813.75 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/no/documents/product-information/elocta-epar-product-information_no.pdf)

polski (PL) (630.86 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/pl/documents/product-information/elocta-epar-product-information_pl.pdf)

português (PT) (549.82 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/pt/documents/product-information/elocta-epar-product-information_pt.pdf)

română (RO) (629.7 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/ro/documents/product-information/elocta-epar-product-information_ro.pdf)

slovenčina (SK) (645.66 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/sk/documents/product-information/elocta-epar-product-information_sk.pdf)

slovenščina (SL) (618.68 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/sl/documents/product-information/elocta-epar-product-information_sl.pdf)

Suomi (FI) (594.99 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/fi/documents/product-information/elocta-epar-product-information_fi.pdf)

svenska (SV) (547.8 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

25/04/2025

[View](/sv/documents/product-information/elocta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000262312 25/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Elocta : EPAR - All Authorised presentations

English (EN) (28.34 KB - PDF)

**First published:** 10/12/2015

**Last updated:** 03/09/2020

[View](/en/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-436)

български (BG) (64.85 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/bg/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.91 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/es/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.79 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/cs/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.32 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/da/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.27 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/de/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.63 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/et/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.5 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/el/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_el.pdf)

français (FR) (26.06 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/fr/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.13 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/hr/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.24 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/is/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.78 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/it/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.37 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/lv/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.9 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/lt/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.57 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/hu/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.98 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/mt/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (28.16 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/nl/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.36 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/no/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.53 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/pl/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.48 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/pt/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.19 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/ro/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.86 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/sk/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.52 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/sl/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.71 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/fi/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.41 KB - PDF)

**First published:**

10/12/2015

**Last updated:**

03/09/2020

[View](/sv/documents/all-authorised-presentations/elocta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Elocta Active substance efmoroctocog alfa International non-proprietary name (INN) or common name efmoroctocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Elocta can be used for all age groups.

## Authorisation details

EMA product number EMEA/H/C/003964 Marketing authorisation holder

Swedish Orphan Biovitrum AB (publ)

SE-112 76

Opinion adopted 23/09/2015 Marketing authorisation issued 18/11/2015 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Elocta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.86 KB - PDF)

**First published:** 25/04/2025

[View](/en/documents/procedural-steps-after/elocta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Elocta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (161.51 KB - PDF)

**First published:** 11/04/2016

**Last updated:** 25/04/2025

[View](/en/documents/procedural-steps-after/elocta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Elocta-H-C-3964-P46-008 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/623021/2021

English (EN) (258.6 KB - PDF)

**First published:** 21/03/2023

[View](/en/documents/variation-report/elocta-h-c-3964-p46-008-epar-assessment-report_en.pdf)

Elocta-H-C-3964-P46-007 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/753870/2021

English (EN) (447.84 KB - PDF)

**First published:** 21/03/2023

[View](/en/documents/variation-report/elocta-h-c-3964-p46-007-epar-assessment-report_en.pdf)

Elocta-H-C-3964-P46-005.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/467869/2019

English (EN) (216.12 KB - PDF)

**First published:** 08/07/2020

[View](/en/documents/variation-report/elocta-h-c-3964-p46-0051-epar-assessment-report_en.pdf)

Elocta-H-C-3964-X-0021 : EPAR - Assessment Report -  Extension

Adopted

Reference Number: EMA/CHMP/697649/2018

English (EN) (391.71 KB - PDF)

**First published:** 15/01/2019

[View](/en/documents/variation-report/elocta-h-c-3964-x-0021-epar-assessment-report-extension_en.pdf)

Elocta-H-C-3964-A31-0006 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/763977/2017

English (EN) (219.85 KB - PDF)

**First published:** 05/12/2017

**Last updated:** 05/12/2017

[View](/en/documents/variation-report/elocta-h-c-3964-a31-0006-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Elocta : EPAR - Public assessment report

Adopted

Reference Number: EMA/671791/2015

English (EN) (5.69 MB - PDF)

**First published:** 10/12/2015

**Last updated:** 10/12/2015

[View](/en/documents/assessment-report/elocta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Elocta

Adopted

Reference Number: EMA/CHMP/557976/2015

English (EN) (68.02 KB - PDF)

**First published:** 25/09/2015

**Last updated:** 25/09/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-elocta_en.pdf)

#### News on Elocta

[Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes](/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between-classes) 15/09/2017

#### More information on Elocta

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu310783) on 20 September 2010. Elocta was withdrawn from the Community register of orphan medicinal products in October 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Elocta

- [EMEA-001114-PIP01-10-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001114-pip01-10-m03)
- [Factor VIII - referral](/en/medicines/human/referrals/factor-viii)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/04/2025

## Share this page

[Back to top](#main-content)